Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2003 Feb 1;369(Pt 3):477–484. doi: 10.1042/BJ20020057

p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor.

Antonio De Luca 1, Anna Severino 1, Paola De Paolis 1, Giuliano Cottone 1, Luca De Luca 1, Maria De Falco 1, Antonio Porcellini 1, Massimo Volpe 1, Gianluigi Condorelli 1
PMCID: PMC1223100  PMID: 12371907

Abstract

Thyroid hormone receptors (TRs) and members of the myocyte enhancer factor 2 (MEF2) family are involved in the regulation of muscle-specific gene expression during myogenesis. Physical interaction between these two factors is required to synergistically activate gene transcription. p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters. We investigated the role of p300 in regulating the TR-MEF2A complex. To this end, we mapped the regions of these proteins involved in physical interactions and we evaluated the expression of a chloramphenicol acetyltransferase (CAT) reporter gene in U2OS cells under control of the alpha-myosin heavy chain promoter containing the thyroid hormone response element (TRE). Our results suggested a role of p300/CBP in mediating the transactivation effects of the TR-retenoid X receptor (RxR)-MEF2A complex. Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex. Moreover, by the use of CAT assays, we demonstrated that adenovirus E1A inhibits activation of transcription by TR-RxR-MEF2A-p300 but not by TR-RxR-MEF2A. Our data suggested that p300 can bind and modulate the activity of TR-RxR-MEF2A at TRE. In addition, it is speculated that p300 might modulate the activity of the TR-RxR-MEF2A complex by recruiting a hypothetical endogenous inhibitor which may act like adenovirus E1A.

Full Text

The Full Text of this article is available as a PDF (274.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonetto F., Fanciulli M., Battista T., De Luca A., Russo P., Bruno T., De Angelis R., Di Padova M., Giordano A., Felsani A. Interaction between the pRb2/p130 C-terminal domain and the N-terminal portion of cyclin D3. J Cell Biochem. 1999 Dec 15;75(4):698–709. doi: 10.1002/(sici)1097-4644(19991215)75:4<698::aid-jcb15>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  2. Chakravarti D., LaMorte V. J., Nelson M. C., Nakajima T., Schulman I. G., Juguilon H., Montminy M., Evans R. M. Role of CBP/P300 in nuclear receptor signalling. Nature. 1996 Sep 5;383(6595):99–103. doi: 10.1038/383099a0. [DOI] [PubMed] [Google Scholar]
  3. Chakravarti D., Ogryzko V., Kao H. Y., Nash A., Chen H., Nakatani Y., Evans R. M. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell. 1999 Feb 5;96(3):393–403. doi: 10.1016/s0092-8674(00)80552-8. [DOI] [PubMed] [Google Scholar]
  4. Guo K., Wang J., Andrés V., Smith R. C., Walsh K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol. 1995 Jul;15(7):3823–3829. doi: 10.1128/mcb.15.7.3823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., Lassar A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 1995 Feb 17;267(5200):1018–1021. doi: 10.1126/science.7863327. [DOI] [PubMed] [Google Scholar]
  6. Izumo S., Mahdavi V. Thyroid hormone receptor alpha isoforms generated by alternative splicing differentially activate myosin HC gene transcription. Nature. 1988 Aug 11;334(6182):539–542. doi: 10.1038/334539a0. [DOI] [PubMed] [Google Scholar]
  7. Janknecht R., Hunter T. Versatile molecular glue. Transcriptional control. Curr Biol. 1996 Aug 1;6(8):951–954. doi: 10.1016/s0960-9822(02)00636-x. [DOI] [PubMed] [Google Scholar]
  8. Lee Y., Nadal-Ginard B., Mahdavi V., Izumo S. Myocyte-specific enhancer factor 2 and thyroid hormone receptor associate and synergistically activate the alpha-cardiac myosin heavy-chain gene. Mol Cell Biol. 1997 May;17(5):2745–2755. doi: 10.1128/mcb.17.5.2745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Li J., O'Malley B. W., Wong J. p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. Mol Cell Biol. 2000 Mar;20(6):2031–2042. doi: 10.1128/mcb.20.6.2031-2042.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Molkentin J. D., Black B. L., Martin J. F., Olson E. N. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell. 1995 Dec 29;83(7):1125–1136. doi: 10.1016/0092-8674(95)90139-6. [DOI] [PubMed] [Google Scholar]
  11. Oberste-Berghaus C., Zanger K., Hashimoto K., Cohen R. N., Hollenberg A. N., Wondisford F. E. Thyroid hormone-independent interaction between the thyroid hormone receptor beta2 amino terminus and coactivators. J Biol Chem. 2000 Jan 21;275(3):1787–1792. doi: 10.1074/jbc.275.3.1787. [DOI] [PubMed] [Google Scholar]
  12. Samuels H. H., Stanley F., Casanova J. Depletion of L-3,5,3'-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology. 1979 Jul;105(1):80–85. doi: 10.1210/endo-105-1-80. [DOI] [PubMed] [Google Scholar]
  13. Sartorelli V., Huang J., Hamamori Y., Kedes L. Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol. 1997 Feb;17(2):1010–1026. doi: 10.1128/mcb.17.2.1010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sartorelli V., Huang J., Hamamori Y., Kedes L. Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol. 1997 Feb;17(2):1010–1026. doi: 10.1128/mcb.17.2.1010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sartorelli V., Webster K. A., Kedes L. Muscle-specific expression of the cardiac alpha-actin gene requires MyoD1, CArG-box binding factor, and Sp1. Genes Dev. 1990 Oct;4(10):1811–1822. doi: 10.1101/gad.4.10.1811. [DOI] [PubMed] [Google Scholar]
  16. Yang S. H., Galanis A., Sharrocks A. D. Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol Cell Biol. 1999 Jun;19(6):4028–4038. doi: 10.1128/mcb.19.6.4028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Yuan W., Condorelli G., Caruso M., Felsani A., Giordano A. Human p300 protein is a coactivator for the transcription factor MyoD. J Biol Chem. 1996 Apr 12;271(15):9009–9013. doi: 10.1074/jbc.271.15.9009. [DOI] [PubMed] [Google Scholar]
  18. Zhao M., New L., Kravchenko V. V., Kato Y., Gram H., di Padova F., Olson E. N., Ulevitch R. J., Han J. Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol. 1999 Jan;19(1):21–30. doi: 10.1128/mcb.19.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES